Healthcare
SpyGlass Pharma, Inc. Common Stock(SGP)
Live Price
Offline$18.44
+1.93% today
Window Change
-31.10%
Window
Feb 6, 2026 โ Jun 9, 2026
- Market Cap
- $760.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 85 bars ยท Feb 6, 2026 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SpyGlass Pharma, Inc. Common Stock (SGP) is a Healthcare stock with a market cap of $760.00M and listed on NASDAQ. The stock last traded around $18.44 and down 31.1% across the available one-year price window (Feb 6, 2026 โ Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines SGP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 8, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -10.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 8, 2026 | โ | -2.9% | โ | โ |
2026 Mar 26, 2026 | -896.1% | -10.3% | -10.9% | -6.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SGP Max Drawdown
-38.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SGP and SPY.
Company Overview
SpyGlass Pharma, Inc. Common Stock
NASDAQ Global Market
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
- Leadership
- Patrick H. Mooney
- IPO Date
- Jan 8, 2008
- Employees
- 1.5k
- Street Address
- 27061 Aliso Creek Road
- Mailing
- Aliso Viejo, CA, 92656
- Region
- Aliso Viejo, CA, US
- Reporting Currency
- USD
- Investor Line
- 1 949 535 0588
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- โ
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.